Adolescent enrollment complete in RUBY gene-editing therapy trial
Enrollment has been completed in the adolescent group of the Phase 1/2/3 RUBY clinical trial testing Editas Medicine’s gene-editing therapy, renizgamglogene autogedtemcel (reni-cel), in people with sickle cell disease (SCD). “I am proud of the Editas team’s work and our advancement in the first half of 2024 as…